Regor’s most advanced orally-administered CDK4/2 inhibitor in the clinic, RGT-419B, will be added to Roche’s pipeline. RGT-419B is a potent CDK4 inhibitor with increased activity on CDK2 ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

In the same period Zolgensma grew 18% to $363 million. Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors to Roche's Genentech for an upfront cash payment of $850 million.

Swiss pharmaceutical giant Roche said Wednesday that it was increasing its capacity to produce diagnostic tests to detect mpox, amid a flare-up of the potentially deadly virus. "We've ramped up ...

Ladies and gentlemen, welcome to Roche Third Quarter Results Webinar ... One is the CDKi portfolio from Regor Therapeutics. The other one is the Wnt portfolio, which is a very important pathway ...

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...

See Correction/Clarification at the end of this article. The Watertown biotech is already working with pharma giants Astellas Pharma Inc. and Novartis AG to engineer capsids for gene therapy delivery.

MANSFIELD — Roche Bros Supermarkets Inc., a 20-store eastern Massachusetts grocery chain under the Roche Bros., Sudbury Farms and Brothers Marketplace banners, said it has entered into a ...

Roche CEO Says More People Have Mpox in Europe Than Has Been Reported By Ludwig Burger FRANKFURT (Reuters) - The CEO of Roche said he has been informed that more cases of mpox infection have ...

Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation ...